During its participation in the Global Health Exhibition 2025 (GHE25), Sudair Pharma signed two strategic agreements aimed at reinforcing Saudi Arabia’s pharmaceutical security, supporting local manufacturing, and advancing national supply chain efficiency.
1. Cooperation Agreement with NUPCO
Sudair Pharma and NUPCO signed a key cooperation agreement focused on strengthening pharmaceutical supply chains across Saudi Arabia. The agreement expands collaboration in local production and distribution of essential and specialized medicines, ensuring continuous availability of life-saving treatments throughout the Kingdom.
Yasser AlObaidah, CEO of Sudair Pharma, emphasized that this partnership highlights the company’s commitment to supporting the Kingdom’s national strategy for localizing drug manufacturing in line with Saudi Vision 2030.
2. Localization Agreement with the Local Content & Government Procurement Authority
In a second major announcement at GHE25, Sudair Pharma signed a strategic agreement with the Local Content & Government Procurement Authority to localize the manufacturing of Bilotinib.
The agreement aims to enhance national pharmaceutical capabilities, support local supply chains, and expand local production of advanced medicines to meet future healthcare demands.
These agreements reflect Sudair Pharma’s continued investment in innovation, industry sustainability, and national pharmaceutical autonomy. They also reinforce the company’s role as a leading contributor to Saudi Arabia’s vision of a resilient and self-reliant healthcare ecosystem.
